Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
Macek Jilkova Z, Aspord C, Kurma K, Granon A, Sengel C, Sturm N, Marche PN,…
Clin Transl Gastroenterol 2019 Jul;10(7):e00058. doi: 10.14309/ctg.0000000000000058. PMID: 31295151; PMCID: PMC6708670.
